Itay Elimelech Gabbay

Itay Elimelech Gabbay

Auto-generated profile, based on publicly available information

Itay Elimelech Gabbay

School of Medicine, Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2011 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
IGItay E. Gabbay
Itay E. Gabbay
PLPeretz Lavie
Peretz Lavie

14 November 2019 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
IGItay Elimelech Gabbay
Itay Elimelech Gabbay
FAFelicity Allen
Felicity Allen
CMChristine Morley
Christine Morley
TPTahmina Pearsall
Tahmina Pearsall
OBOliver Martyn Bowes
Oliver Martyn Bowes
SRSimon Ruben
Simon Ruben
Aim To report efficacy and safety measures for XEN45 in a National Health Service setting after 24-month follow-up. Methods This is a retrospective, non-comparative audit of records of patients who underwent XEN45 procedure between June 2015 and May 2017. The main outcome measures were intraocular pressure (IOP) reduction and number of antihypertensive medications at each timepoint. Failure was defined as requiring further surgery or removal of XEN. Success was defined as 20% reduction of IOP without additional glaucoma medications or reduction in antihypertensive medications without increase in baseline IOP. Needling rates were assessed and subgroup analysis was performed. Results A total of 151 eyes were included in the study. The main diagnoses were primary open angle glaucoma (84.1%), angle closure glaucoma (8.6%) and refractory glaucoma (7.3%). Stand-alone procedure was performed in 62.3% and combined phaco-XEN was done in 37.7%. The mean IOP at baseline was 22.1±6.5 mm Hg, and the mean IOP at 12 and 24 months was 15.4±5.9 mm Hg and 14.5±3.3 mm Hg, respectively (p<0.001). The mean number of medications was 2.77±1.1 at baseline, and 0.3±0.7 and 0.5±1.0 medications at 12 and 24 months, respectively (p<0.001). 25% of patients failed at the 24-month timepoint. Needling was required in 37.7% of patients at 24 months. Non-Caucasian ethnicity was found to be related to higher failure rate. No significant adverse events were noted. Conclusion XEN45 is a viable, effective and safe procedure after 2 years of follow-up. Patients should be advised regarding failure rate as well as possible need for bleb revisions and medication use.

2 May 2021 in European Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
IGItay E Gabbay
Itay E Gabbay
MGMordechai Goldberg
Mordechai Goldberg
FAFelicity Allen
Felicity Allen
ZLZhiheng Lin
Zhiheng Lin
CMChristine Morley
Christine Morley
SRSimon Ruben
Simon Ruben
To report efficacy and safety measures of the XEN45 gel stent at 36 months in the UK National Health Service setting. Retrospective non-comparative audit of the records of patients who underwent XEN45 implantation between June 2015 and May 2017 was performed. Main outcome measures were intraocular pressure and number of antihypertensive medications used. Failure was defined as need for further surgery or stent removal. Success was defined as a 20% decrease in intraocular pressure without the need for additional glaucoma medications or a reduction in antihypertensive medications without an increase in baseline intraocular pressure. Needling rates and preoperative factors effect were assessed. The cohort included 205 patients (205 eyes) with primary open angle glaucoma (84.4%), angle closure glaucoma (7.8%), or refractory glaucoma (7.8%), 62.9% had a stand-alone procedure and 37.1%, a combined phaco-XEN45 procedure. Mean intraocular pressure was 22.6 ± 7.0 mmHg at baseline compared to 14.7 ± 3.8 mmHg at 24 months and 14.0 ± 2.9 mmHg at 36 months (p < 0.001 for both). Mean number of medications used was 2.6 ± 1.1 at baseline compared to 0.5 ± 0.9 and 0.6 ± 1.0, at 24- and 36-months, respectively (p < 0.001 for both). The failure rate at 36 months was 25%. Needling was required in 36.6%. Evaluation of background factors yielded an increased failure rate in non-Caucasians compared to Caucasians (74% vs 21%, p < 0.001). XEN45 implantation is effective and safe at 36 months’ follow-up. Patients should be advised regarding the risk of failure and possible need for bleb revisions. Careful patient selection may be required.

1 May 2012 in Sleep Medicine
Verified
Journal Article
Closed access
IGItay E. Gabbay
Itay E. Gabbay
UGUri Gabbay
Uri Gabbay
PLPeretz Lavie
Peretz Lavie

29 April 2017 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
IGI. E. Gabbay
I. E. Gabbay
IBI. Bahar
I. Bahar
YNY. Nahum
Y. Nahum
ELE. Livny
E. Livny

1 December 2019 in Journal of Current Glaucoma Practice
Verified
Journal Article
Open access
IGItay E Gabbay
Itay E Gabbay
SRSimon Ruben
Simon Ruben
The suprachoroidal pathway can potentially provide a viable target for intraocular pressure (IOP) control. We present efficacy and safety result for the CyPass® Micro-Stent that provides insight into the use of the suprachoroidal space for IOP reduction. A retrospective, noncomparative audit of patient records in a university-affiliated National Health Service (NHS) hospital between June 2017 and August 2018. Main outcome measures were IOP reduction and the number of glaucoma drops taken at each time point. Failure and adverse events were noted for each patient. Seventy-seven consecutive case records of 69 patients underwent the CyPass® procedure between August 2017 and August 2018. A stand-alone procedure was performed in 37 (58%) of cases and combined phacoemulsification and CyPass® procedures were performed in 27 (42%) of cases. At baseline, the mean IOP was 24.6 ± 7.2 mm Hg. The mean IOP at 12 months' follow-up was 16.4 ± 4.5 mm Hg (p < 0.05). At baseline, the mean number of medications was 2.41 ± 0.98, which decreased at 12 months to 1.1 ± 1.3 (p < 0.05). Best corrected visual acuity analysis did not show statistically significant change preoperatively and at each postoperative time point. At 12 months' postoperative time point, 24% of eyes had failed. Significant IOP spikes were noted in 18 (28.1%) of cases. The suprachoroidal pathway appears to potentially offer an alternative to the classic subconjunctival pathways, yet present a new set of challenges. Further studies would have to address these concerns of endothelial cell loss, IOP spikes, and high failure rate. Gabbay IE, Ruben S. CyPass® Micro-Stent Safety and Efficacy at One Year: What Have We Learned? J Curr Glaucoma Pract 2019;13(3):99-103.